Clinical Trial Update: Photoallergic Potential of 6% Bemotrizinol [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the photoallergic potential of 6% bemotrizinol has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Photoallergic Response

Drugs mentioned

• bemotrizinol (bemotrizinol)

Snippet

Sponsor: dsm-firmenich Switzerland AG | Conditions: Photoallergic Response | Phase 2 | Status: COMPLETED